REGIMENTED PHOSPHODIESTERASE TYPE 5 INHIBITOR USE REDUCES EMERGENCY DEPARTMENT VISITS FOR RECURRENT ISCHEMIC PRIAPISM

被引：0

作者：

Hou, L. ^{[1
]}

Burnett, A. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA

来源：

JOURNAL OF SEXUAL MEDICINE | 2021年 / 18卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

122

引用

页码：S64 / S65

页数：4

共 50 条

[41] Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause mortality in patients with coronary artery disease
Anderson, S. G.
Hutchings, D. C.
Rahimi, K.
Woodward, M.
Heald, A. H.
EUROPEAN HEART JOURNAL, 2015, 36 : 643 - 643
[42] Cases of Ischemic Optic Neuropathy Associated With Phosphodiesterase-5 Inhibitor Use Reported to the Food and Drug Administration Adverse Event Reporting System
Pomeranz, Howard D.
JOURNAL OF NEURO-OPHTHALMOLOGY, 2016, 36 (02) : 221 - 222
[43] A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy
Gallina, Andrea
Bianchi, Marco
Gandaglia, Giorgio
Cucchiara, Vito
Suardi, Nazareno
Montorsi, Francesco
Briganti, Alberto
EUROPEAN UROLOGY, 2015, 68 (05) : 750 - 753
[44] Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men
D M Lee
J Nazroo
N Pendleton
International Journal of Impotence Research, 2015, 27 : 146 - 151
[45] Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men
Lee, D. M.
Nazroo, J.
Pendleton, N.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2015, 27 (04) : 146 - 151
[46] Chronic Phosphodiesterase Type 5 Inhibitor Therapy Reduces Priapic Activity in Transgenic Sickle Cell Mice: Restoring Nitric Oxide/Redox Balance in the Penis
Burnett, Arthur L.
Musicki, Biljana
Champion, Hunter C.
Bivalacqua, Trinity J.
BLOOD, 2009, 114 (22) : 239 - 239
[47] Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure
Flahavan, Evelyn M.
Li, Hu
Gupte-Singh, Komal
Rizk, Rosemary T.
Ruff, Dustin D.
Francis, Jennie Lin
Kinchen, Kraig S.
UROLOGY, 2017, 105 : 76 - 83
[48] RISK OF MELANOMA WITH PHOSPHODIESTERASE TYPE 5 INHIBITOR USE AMONGST PATIENTS WITH ERECTILE DYSFUNCTION, PULMONARY HYPERTENSION AND LOWER URINARY TRACT SYMPTOMS
Shkolyar, Eugene
Li, Shufeng
Tang, Jean
Eisenberg, Michael
JOURNAL OF UROLOGY, 2018, 199 (04): : E1169 - E1169
[49] THE EFFECTS OF THE COMBINED USE OF A PHOSPHODIESTERASE TYPE 5 INHIBITOR AND MEDICATIONS FOR HYPERTENSION, LOWER URINARY TRACT SYMPTOMS, AND DYSLIPIDEMIA ON CORPORAL TISSUE TONE
Lee, J. H.
Chae, M. R.
Park, J. K.
Jeon, J. H.
Lee, S. W.
JOURNAL OF SEXUAL MEDICINE, 2011, 8 : 411 - 411
[50] Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms
Shkolyar, Eugene
Li, Shufeng
Tang, Jean
Eisenberg, Michael L.
JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : 982 - 989

← 1 2 3 4 5 →